JP2005538935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538935A5 JP2005538935A5 JP2003571482A JP2003571482A JP2005538935A5 JP 2005538935 A5 JP2005538935 A5 JP 2005538935A5 JP 2003571482 A JP2003571482 A JP 2003571482A JP 2003571482 A JP2003571482 A JP 2003571482A JP 2005538935 A5 JP2005538935 A5 JP 2005538935A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cell
- group
- dosage form
- oxygen species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 7
- 108010012715 Superoxide dismutase Proteins 0.000 claims 7
- 229910052755 nonmetal Inorganic materials 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 5
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 239000006204 intramuscular dosage form Substances 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 239000006207 intravenous dosage form Substances 0.000 claims 4
- 230000003278 mimic effect Effects 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 239000006203 subcutaneous dosage form Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical group C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims 1
- -1 carboxy fullerenes Chemical class 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229910003472 fullerene Inorganic materials 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/083,283 US20030162837A1 (en) | 2002-02-23 | 2002-02-23 | Carboxyfullerenes and methods of use thereof |
| PCT/US2003/005332 WO2003072802A2 (en) | 2002-02-23 | 2003-02-20 | Carboxyfullerenes and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538935A JP2005538935A (ja) | 2005-12-22 |
| JP2005538935A5 true JP2005538935A5 (enExample) | 2006-04-06 |
Family
ID=27753271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571482A Withdrawn JP2005538935A (ja) | 2002-02-23 | 2003-02-20 | カルボキシフラーレンおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030162837A1 (enExample) |
| EP (1) | EP1476150A4 (enExample) |
| JP (1) | JP2005538935A (enExample) |
| AU (1) | AU2003213206A1 (enExample) |
| CA (1) | CA2476782A1 (enExample) |
| WO (1) | WO2003072802A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7145032B2 (en) * | 2002-02-23 | 2006-12-05 | Washington University | Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
| US20050058675A1 (en) * | 2003-04-10 | 2005-03-17 | Wilson Stephen R. | Fullerene compositions for ameliorating dermatological conditions |
| US20060247152A1 (en) * | 2005-05-02 | 2006-11-02 | Russ Lebovitz | Substituted fullerenes and their use as inhibitors of cell death |
| US20050288236A1 (en) * | 2003-10-10 | 2005-12-29 | Russ Lebovitz | Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death |
| US7163956B2 (en) * | 2003-10-10 | 2007-01-16 | C Sixty Inc. | Substituted fullerene compositions and their use as antioxidants |
| US7825161B2 (en) * | 2003-12-15 | 2010-11-02 | Nano-C, Inc. | Higher fullerenes useful as radical scavengers |
| WO2006028635A2 (en) * | 2004-09-02 | 2006-03-16 | C Sixty Inc. | Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis |
| JP2006160664A (ja) * | 2004-12-07 | 2006-06-22 | Vitamin C60 Bioresearch Kk | フリーラジカル疾患予防治療用組成物 |
| US20060188723A1 (en) * | 2005-02-22 | 2006-08-24 | Eastman Kodak Company | Coating compositions containing single wall carbon nanotubes |
| US20070292622A1 (en) * | 2005-08-04 | 2007-12-20 | Rowley Lawrence A | Solvent containing carbon nanotube aqueous dispersions |
| US20080020977A1 (en) * | 2005-11-21 | 2008-01-24 | Russ Lebovitz | Use of Fullerenes to Oxidize Reduced Redox Proteins |
| US20090123893A1 (en) * | 2007-06-08 | 2009-05-14 | Alleman David S | Method of performing and teaching adhesive dentistry |
| EP2259786A4 (en) * | 2008-03-03 | 2011-03-09 | Luna Innovations Inc | METHOD FOR PREVENTING THE CONSTITUTION OF AN ARTERIAL PLAQUE BY ADMINISTERING FULLERENES |
| US20110003773A1 (en) * | 2008-03-03 | 2011-01-06 | Luna Innovations Incorporated | Using fullerenes to enhance and stimulate hair growth |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| JP6216493B2 (ja) * | 2011-06-24 | 2017-10-18 | 国立大学法人 香川大学 | 寿命延長剤 |
| TN2011000327A1 (en) * | 2011-06-30 | 2012-12-17 | Fathi Moussa | Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals |
| US20200188339A1 (en) | 2018-12-14 | 2020-06-18 | Max Champie | Nutraceutical Composition Comprising C60 And Ketone Esters |
| US11400113B2 (en) | 2019-08-08 | 2022-08-02 | Innovation for Success, LLC | Dissolved C60 and method of producing dissolved C60 |
| US12491209B2 (en) | 2019-08-08 | 2025-12-09 | Innovation for Success, LLC | Dissolved C60 and method of producing dissolved C60 |
| US11484508B2 (en) | 2019-08-08 | 2022-11-01 | Innovation for Success, LLC | Dissolved C60 and method of producing dissolved C60 |
| US10842742B1 (en) | 2019-08-08 | 2020-11-24 | Innovation for Success, LLC | Dissolved C60 and method of producing dissolved C60 |
| US12274713B2 (en) | 2021-05-07 | 2025-04-15 | Max C. Champie | Nutraceutical composition comprising a water-soluble fullerene and a ketone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705781A (en) * | 1986-10-08 | 1987-11-10 | Giba-Geigy Corporation | Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof |
| JPH01316328A (ja) * | 1988-06-15 | 1989-12-21 | Mitsui Toatsu Chem Inc | 老化防止、細胞賦活、老人病予防・治療のための薬剤 |
| DE4313481A1 (de) * | 1993-04-24 | 1994-10-27 | Hoechst Ag | Fullerenderivate, Verfahren zur Herstellung und deren Verwendung |
| US5648523A (en) * | 1995-10-26 | 1997-07-15 | Chiang Long Y | Fullerene derivatives as free-radical scavengers |
| CA2255913C (en) * | 1996-06-03 | 2007-07-31 | F. Hoffmann-La Roche Ag | The use of buckminsterfullerene for treatment of neurotoxic injury |
| US6265443B1 (en) * | 1996-06-03 | 2001-07-24 | Washington University | Method for treating neuronal injury with carboxyfullerene |
| JP2001097888A (ja) * | 1999-09-28 | 2001-04-10 | Hiroshi Ikeno | 外用組成物 |
| TWI250874B (en) * | 2000-03-24 | 2006-03-11 | Nat Health Research Institutes | Pharmaceutical compositions for preventing or treating disorders associated with bacterial or viral infection |
| MXPA02011528A (es) * | 2000-05-25 | 2003-04-25 | Pharmaton Sa | Metodo para mejorar la proteccion celular. |
| US6538153B1 (en) * | 2001-09-25 | 2003-03-25 | C Sixty Inc. | Method of synthesis of water soluble fullerene polyacids using a macrocyclic malonate reactant |
| US7145032B2 (en) * | 2002-02-23 | 2006-12-05 | Washington University | Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
-
2002
- 2002-02-23 US US10/083,283 patent/US20030162837A1/en not_active Abandoned
-
2003
- 2003-02-20 CA CA002476782A patent/CA2476782A1/en not_active Abandoned
- 2003-02-20 JP JP2003571482A patent/JP2005538935A/ja not_active Withdrawn
- 2003-02-20 WO PCT/US2003/005332 patent/WO2003072802A2/en not_active Ceased
- 2003-02-20 AU AU2003213206A patent/AU2003213206A1/en not_active Abandoned
- 2003-02-20 EP EP03709252A patent/EP1476150A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003072802A3 (en) | Carboxyfullerenes and methods of use thereof | |
| Ban et al. | Potential biomedical limitations of graphene nanomaterials | |
| Abild-Pedersen et al. | Mechanisms for catalytic carbon nanofiber growth studied by ab initio density functional theory calculations | |
| Crane et al. | The essential functions of coenzyme Q | |
| Kia et al. | A first-principles study of functionalized clusters and carbon nanotubes or fullerenes with 5-Aminolevulinic acid as vehicles for drug delivery | |
| Sekhon | Exploiting the power of stereochemistry in drugs: an overview of racemic and enantiopure drugs | |
| JP2007529532A5 (enExample) | ||
| JP2010513363A5 (enExample) | ||
| JP2008501615A5 (enExample) | ||
| Wu et al. | ZIF‐67‐Derived Antivirus Cobalt Hydroxide LDH Nanosheets Produced through High‐Concentration Cobalt Ion‐Assisted Hydration | |
| MY137282A (en) | New azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | |
| Yang et al. | Biomimetic-structured cobalt nanocatalyst suppresses aortic dissection progression by catalytic antioxidation | |
| Sundaramoorthy et al. | Crystal structure and preliminary functional analysis of the cytochrome c peroxidase His175Gln proximal ligand mutant | |
| Saikia | Functionalized carbon nanomaterials in drug delivery: emergent perspectives from application | |
| Feng et al. | Multilayered structure and activity of electroactive biofilms in response to the switch from microbial fuel cell to microbial electrolysis cell | |
| Han et al. | Growth of carbon nanotubes on graphene as 3D biocathode for NAD+/NADH balance model and high-rate production in microbial electrochemical synthesis from CO 2 | |
| Shao et al. | Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review | |
| Myers et al. | Insights into the mechanism of DNA cleavage by dynemicin A as revealed by DNA-binding and-cleavage studies of synthetic analogs | |
| JP2002542256A5 (enExample) | ||
| JP2011516572A5 (enExample) | ||
| WO2009099673A1 (en) | Ruthenium compounds and compositions | |
| Zamel et al. | Biofunctionalization of carbon nanostructures | |
| Zhu et al. | Electrochemical study of a hemin–DNA complex and its activity as a ligand binder | |
| EP2407176A4 (en) | Improvement agent for chronic obstructive pulmonary disease | |
| Rosen et al. | Carbon nanotubes and infectious diseases |